Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. (NUS) Market Cap

Nu Skin Enterprises, Inc. has a market capitalization of $260.7M.

Price: $5.37

0.05 (0.94%)

Market Cap: 260.72M

NYSE · time unavailable

CEO: Ryan S. Napierski

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1996-11-22

Website: https://www.nuskin.com

Nu Skin Enterprises, Inc. (NUS) - Company Information

Market Cap: 260.72M|Sector: Consumer Defensive

Company Profile

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

Analyst Sentiment

60%
Buy

From 0 Active Polls

1Y Forecast: $11.00

▲ +104.8% Potential Upside

Consensus Target Metrics

Low Bound

$11

Median

$11

High Bound

$11

Average

$11

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$11.00
▲ +104.84% Upside
Low Target
$11.00
105% Risk
Median Target
$11.00
105% Mid
High Target
$11.00
105% Max
Consensus
Hold
0 / 11 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)261351467602395361343366517
Enterprise Value ($M)340430593642442458634640821
Price to Earnings Ratio (P/E)4.7547.788.068.814.680.84-2.3711.03-1.09
Price/Earnings-to-Growth Ratio (PEG)4.810.79-0.66-0.21
Price to Sales Ratio (P/S)0.181.091.261.651.020.990.770.851.18
Price to Book Ratio (P/B)0.330.440.580.750.500.480.530.520.75
Price to Free Cash Flow Ratio (P/FCF)6.27-19.9079.7434.2811.04-27.3825.9416.0411.99
Enterprise Value to Sales (EV/Sales)1.341.601.761.141.261.421.491.87
Enterprise Value to EBITDA (EV/EBITDA)2.6223.6116.4019.9110.273.01-17.8617.25-7.65
Debt to Equity Ratio0.610.350.450.360.390.400.730.710.77

NUS Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$5.37
Intrinsic Value$5.36
Market Alignment
Overvalued by 0.2%relative to calculated intrinsic value
9.00%
Exp: -10%-10%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.04B
Perpetuity TV Value$0.69B
Discounted TV (PV)$0.29B
TV Weighting %49.4%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 NU SKIN ENTERPRISES INC CLASS A (NUS) — Investment Overview

🧩 Business Model Overview

Nu Skin operates a direct-selling model for personal care and beauty products, selling primarily through a network of independent sales representatives. The value chain centers on (1) product development and supply sourcing, (2) marketing and education provided to the distributor network, and (3) repeat purchasing driven by customer and distributor engagement programs. Unlike traditional retail, the company’s commercial infrastructure is distributed: product discovery, replenishment, and customer acquisition are heavily enabled by ongoing interpersonal selling and brand education delivered through the independent channel.

In this model, stickiness derives from relationship depth within the distributor-to-customer ecosystem and from the operational effort required to replicate comparable product education, merchandising, and localized compliance practices across markets.

💰 Revenue Streams & Monetisation Model

Revenue is generated primarily from product sales to customers and distributors (with sales typically flowing through the independent channel rather than through company-owned stores). Monetisation is supported by:

  • Repeat purchasing behavior: personal care and beauty categories naturally support replenishment cycles, which can translate into recurring demand when customers maintain ongoing consumption habits.
  • Volume-linked distributor economics: distributor incentives are structured around sales performance, which supports continued customer solicitation and inventory movement through the network.
  • Mix and margin discipline: gross margin and operating leverage depend on product mix (premium skincare/supplements versus commoditized SKUs), promotional intensity, freight and logistics efficiency, and inventory management.

Margin drivers generally hinge on (1) stable unit demand that absorbs fixed SG&A, (2) product sourcing and manufacturing cost control, and (3) the company’s ability to maintain pricing power and reduce channel friction (including chargebacks/returns risk where applicable).

🧠 Competitive Advantages & Market Positioning

Nu Skin’s moat is best characterized as a combination of network effects and intangible assets, reinforced by switching costs created by relationship- and routine-based purchasing.

Moat mechanics:

  • Network effects (two-sided engagement): A larger and more active distributor base increases product education capacity, lowers the effective customer acquisition cost, and improves distributor recruitment prospects—supporting continued channel utilization.
  • Switching costs: Customers often buy through a trusted representative and follow regimen-based product routines; shifting to competitors requires rebuilding trust, finding new product guidance, and restarting routines.
  • Intangible assets: long-standing product know-how, formulation/ingredient expertise, and distribution/market-access capabilities are difficult to replicate quickly across regions.

Competitive benchmarking:

  • Herbalife (HLF): competes in nutrition and personal care via a similar direct-selling framework. Nu Skin’s industry focus skews more toward premium skincare and beauty positioning, while Herbalife has a heavier nutrition-centric portfolio emphasis.
  • Amway (Alticor): broad wellness and household ecosystem with large scale and extensive channel reach. Amway benefits from scale economics across categories; Nu Skin competes by leaning into a narrower beauty/personal care focus and specialist product education.
  • Avon (Altice/Avon-branded channel) (and peer direct sellers like Mary Kay): competes in beauty through representative networks. Nu Skin differentiates through its product formulation/beauty regimen positioning and direct-selling program design tailored to its specific customer base.

Relative to these rivals, the competitive challenge for entrants is not only product development—it is the build-out of compliant, market-specific distribution systems that can sustain training depth, customer education, and repeat purchase economics over time.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is most plausibly driven by secular tailwinds that benefit direct-selling ecosystems and by selective expansion in reachable geographies and channels:

  • Global demand for skincare and personal care: aging demographics, rising discretionary spend in emerging markets, and increasing consumer emphasis on appearance/skin health support category expansion.
  • Distributor productivity and retention: improving training, tools, and sales enablement can raise output per active representative and stabilize customer cohorts, supporting a more durable revenue base.
  • Digital and hybrid selling enablement: supplementing traditional relationship-based selling with digital workflows can improve customer engagement and reduce acquisition costs, supporting higher conversion and repeat rates.
  • Portfolio optimization: shifting toward higher-margin SKUs and bundling regimen-based consumption can strengthen gross margin and increase lifetime value.
  • Market expansion within regulatory constraints: sustainable growth requires careful compliance execution, leveraging the company’s existing know-how in localized product registration and channel governance.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: direct-selling practices face scrutiny related to marketing claims, territory rules, and incentive program governance. Product ingredient and labeling compliance also varies by market.
  • Channel concentration and distributor churn: revenue performance can be sensitive to representative attrition, productivity swings, and the ability to recruit and retain sales leaders.
  • Reputational and consumer-safety risk: adverse events tied to product quality, labeling accuracy, or substantiation of claims can create costly remediation and harm demand.
  • Competitive intensity: well-capitalized direct sellers and large incumbents can pressure pricing and promotional budgets, reducing margin headroom.
  • Supply chain and inventory risk: demand forecasting errors can lead to higher inventory levels, promotional write-downs, and cash flow pressure.
  • Foreign exchange and macro sensitivity: revenue from international markets can be exposed to currency movements and consumer discretionary cycles.

📊 Valuation & Market View

Equity markets often value direct-selling and consumer-oriented businesses using a blend of price-to-sales (P/S) and EV/EBITDA, with fundamentals anchored to revenue durability, distributor productivity, and operating margin sustainability. Key variables that typically move valuation include:

  • Revenue growth quality: evidence that growth is supported by repeat purchasing and healthy channel velocity rather than short-term promotions.
  • Gross margin resilience: product mix, sourcing efficiency, and promotional intensity.
  • Operating leverage: the degree to which operating expenses scale with distributor output without requiring proportionate spend increases.
  • Channel health: active representative base trends, retention, and the sustainability of recruitment.
  • Regulatory overhang: changes in marketing claim standards and enforcement intensity can affect both revenue and cost structure.

🔍 Investment Takeaway

Nu Skin’s long-term investment case rests on a structurally sticky direct-selling ecosystem. The company’s differentiating assets are relationship-driven switching costs, engagement-driven network effects, and developed intangible capabilities in product education and compliant distribution execution. While competition and regulatory scrutiny remain persistent, the durability of customer routines and distributor productivity can support a resilient revenue base and margin discipline when channel governance and portfolio optimization are executed effectively.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for NUS.

seekingalpha.com2026-06-04

13 Lucky Dogs: June Graham Value All-Stars (GVAS)

The June GVAS portfolio highlights 13 'safer,' fair-priced large-cap value stocks with strong dividend yields and positive free cash flow margins. Top ten GVAS stocks are forecasted to deliver average net gains of 39.68% by June 2027, with yields ranging from 7.9% to 16.46%. Energy and financial sectors dominate the highest-yielding, lowest-priced GVAS, with Okeanis Eco Tankers and IRSA Inversiones offering standout upside potential.

zacks.com2026-06-02

5 Bargain Low Price-to-Sales Stocks Positioned to Deliver Solid Gains

Price-to-sales screens can uncover discounted growth when earnings are thin, pairing low P/S with balance-sheet and value checks for upside.

zacks.com2026-05-21

5 Value Stocks Trading at Attractive Price-to-Sales Ratios

Low price-to-sales stocks like SCVL, NUS, APLE, COP and FAF screen as undervalued, with the setup hinging on debt levels, strong cash flow and business momentum.

zacks.com2026-05-20

3 Cosmetics Stocks Gaining From AI, Wellness and Innovation Trends

EL, NUS and COTY tap AI, wellness and innovation trends as beauty demand evolves across skincare, cosmetics and fragrance categories.

businesswire.com2026-05-15

Nu Skin Reaches 900 Million Meals Purchased and Donated in its Global Fight for Child Nutrition

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS), a global leader in beauty and wellness, today announced it has reached the milestone of providing 900 million meals for children since 2002 through its Nourish the Children initiative. Malnourished children in more than 65 countries around the world have been fed VitaMeal,* a nutrient-dense food, from one of the company's third-party charity partners after Nu Skin sales leaders, customers or employees purchase and donate bags.

marketbeat.com2026-05-13

Nu Skin Enterprises Q1 Earnings Call Highlights

Nu Skin Enterprises NYSE: NUS reported first-quarter 2026 results that management said were in line with expectations, as the company continued to invest in its Prysm iO wellness platform and emerging-market expansion while navigating macroeconomic pressures on consumers and supply chains.

newsfilecorp.com2026-05-08

Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 1Q26

Dallas, Texas--(Newsfile Corp. - May 8, 2026) - NU Skin Enterprises Inc. (NYSE: NUS): Stonegate Capital Partners updates their coverage on NU Skin Enterprises Inc. (NYSE: NUS). NUS reported revenue, adj NI, and adj EPS of $320.6M, $6.8M, and $0.14, respectively.

seekingalpha.com2026-05-08

Nu Skin Enterprises, Inc. (NUS) Q1 2026 Earnings Call Transcript

Nu Skin Enterprises, Inc. (NUS) Q1 2026 Earnings Call Transcript

zacks.com2026-05-07

Nu Skin Enterprises (NUS) Q1 Earnings and Revenues Lag Estimates

Nu Skin Enterprises (NUS) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.23 per share a year ago.

businesswire.com2026-05-07

Nu Skin Enterprises Reports First Quarter Results

PROVO, Utah--(BUSINESS WIRE)---- $NUS--Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% “We del.

businesswire.com2026-05-07

Nu Skin Enterprises Announces Quarterly Dividend

PROVO, Utah--(BUSINESS WIRE)---- $NUS--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scient.

seekingalpha.com2026-04-24

Buy 14 Ideal Graham Value All-Stars Of 27 'Safer' Dividends In 71 April/May GVAS

The April/May 2026 Ben Graham All-Star Value Dogs list highlights 14 'safer,' fair-priced large-cap value stocks with robust, reliable dividends. Analyst forecasts project average net gains of 39.88% by April/May 2027 for the top ten yielding GASV stocks, with risk profiles generally below market average. Dividend safety is emphasized: 27 of 71 GASV names are 'safer' by free cash flow, but only 14 are both 'safer' and fairly priced for immediate purchase.

businesswire.com2026-04-13

Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release first quarter 2026 results after the market closes on Thursday, May 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor.

businesswire.com2026-04-02

Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS), the world's #1 company for beauty and wellness device systems,* today announced the general consumer availability in the U.S. of Prysm iO™, a breakthrough intelligent nutritional wellness platform designed to deliver a better understanding of how daily nutrition and supplement routines support overall wellness. Prysm iO will launch for consumers in other Nu Skin markets in the coming months. Compact, portable and powered by adv.

seekingalpha.com2026-04-02

71 April Graham Value All-Stars (GVAS): 14 To Buy

The April 2026 GASV list highlights 14 fair-priced, 'safer' mid-to-large-cap value stocks with strong dividend profiles and positive free-cash-flow-yields. Top ten GASV stocks are projected to deliver average net gains of 43.98% by April 2027, with yields ranging from 7.47% to 13.59%. All top-ten GASV stocks are ideally priced, with dividends from $1K invested exceeding their share prices, though some financials fund dividends with borrowed money.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"NUS reported Q1 2026 revenue of $320.6M and net income of $1.84M (EPS $0.04). On a YoY basis, revenue fell (Q1 2026: -11.99% vs Q1 2025), while net income declined sharply (Q1 2026: -98.29% vs Q1 2025). QoQ, revenue decreased (Q1 2026: -13.41% vs Q4 2025) and net income also fell (Q1 2026: -87.30%). Profitability deteriorated meaningfully: gross margin was 66.9% in Q1 2026 versus 70.7% in Q4 2025, while operating margin collapsed to 1.26% (from 6.28% in Q4). Net margin dropped to 0.57% from 3.91% QoQ, indicating cost leverage and/or demand softness. Cash flow quality weakened as operating cash flow was -$3.9M and free cash flow was -$17.6M in Q1 2026, contrasting with positive operating and free cash flow in prior quarters. Balance sheet liquidity remains adequate: cash and equivalents were $198.7M and total equity was $794.1M, broadly stable QoQ. The company repurchased shares (-$5.0M) and paid dividends (-$2.9M) in the quarter. Shareholder returns look strong due to market momentum: the stock is up 40.82% over the last year (dividend yield ~0.8% noted from ratios), driving total return even though earnings have weakened."

Revenue Growth

Caution

Revenue declined QoQ (-13.41%) and YoY (-11.99%), suggesting contracting demand or weaker volume/pricing.

Profitability

Neutral

Margins contracted materially: operating margin fell to 1.26% from 6.28% QoQ; net margin fell to 0.57% from 3.91% QoQ. Net income YoY declined -98.29%.

Cash Flow Quality

Neutral

Q1 2026 operating cash flow was -$3.9M and free cash flow was -$17.6M, deteriorating versus prior quarters’ positive cash generation.

Leverage & Balance Sheet

Neutral

Liquidity is supported (cash $198.7M) and equity is stable ($794.1M). Net debt was lower QoQ ($79.0M vs $125.6M), indicating improving resilience.

Shareholder Returns

Good

Strong price momentum with 1y_change of +40.82%. Dividend yield is modest (~0.8%), and buybacks/dividends were still executed in Q1.

Analyst Sentiment & Valuation

Caution

Price target consensus is ~$11 versus current price ~$7.90 (upside implied), but the underlying earnings and cash flow trend have weakened, tempering conviction.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Nu Skin reported Q1 2026 results in line with expectations: revenue of $320.6M and adjusted EPS of $0.14 (GAAP EPS $0.04). Margin dynamics were mixed—adjusted gross margin improved slightly (+10 bps consolidated; +20 bps in core), but investment drove profitability down as selling expense rose materially (+180 bps consolidated; +180 bps in core) and G&A increased (+100 bps), resulting in adjusted operating margin of 3.6% (-280 bps YoY). The strategic emphasis remains Prysm iO and emerging markets. Prysm iO showed early engagement momentum with subscription volume up 5% YoY and subscribers as a share of total customers up 14%, alongside >10% YoY LifePak growth and stronger Prysm-certified product performance. Macro risk is acknowledged (tariffs, fuel, consumer strain), but guidance assumes no significant impact currently. For India, management reiterated a disciplined, learning-focused approach: formal launch by year-end, limited 2026 revenue forecast, and ramp thereafter.

AI IconGrowth Catalysts

  • Prysm iO rollout driving wellness device adoption and expanding engagement via personalized wellness assessment (15-second fingertip scan).
  • Early subscription momentum: subscription volume +5% YoY and subscribers as % of total customers +14%.
  • LifePak growth: flagship LifePak grew >10% YoY and products certified to raise Prysm iO score outperform total product sales.
  • Mainland China improving leader engagement around Tru Face anti-aging rollout.
  • Latin America sustained growth from sales leader execution.

Business Development

    AI IconFinancial Highlights

    • Revenue: $320.6M, within guidance; +1% favorable foreign currency impact.
    • EPS: GAAP EPS $0.04 vs adjusted EPS $0.14; adjusted EPS in line with guidance (excluding wind-down costs for BeautyBio and other charges).
    • Adjusted gross margin 67.9% vs 67.8% prior year (+10 bps).
    • Core Nu Skin gross margin 76.9% vs prior year (+20 bps), attributed to operational efficiency and product mix optimization.
    • Consolidated selling expense 34.3% of revenue vs 32.5% prior year (+180 bps), with core selling expense 40.5% vs 38.7% (+180 bps).
    • G&A 29.9% of revenue vs 28.9% prior year (+100 bps), driven by ongoing investments in technology and emerging market expansion (incl. India).
    • Adjusted operating margin 3.6% vs 6.4% prior year (-280 bps), reflecting elevated selling and G&A as investment continues.
    • Gen/administrative absolute change: declined by $9M YoY on an adjusted basis.
    • Guidance sensitivity: Q2 revenue range $330M-$360M; EPS $0.15-$0.25; guidance assumes relatively neutral foreign currency.

    AI IconCapital Funding

    • Shareholder returns in Q1: approx. $8M total ($3M dividends, $5M share repurchases).
    • Remaining authorization: $137.3M under current share repurchase authorization.
    • Refinanced credit facilities during quarter: extended maturities through 2031 and improved borrowing costs; refinance proceeds used to repay existing indebtedness.
    • No explicit ending cash balance or net debt provided; liquidity profile characterized as strong and extended through 2031.

    AI IconStrategy & Ops

    • Switching business model for Prysm iO: training and enablement shifting leaders from product demonstration tool toward household wellness device positioning with ongoing personalized insights.
    • AI integration: Prysm iO AI supports scoring, data comparisons, and personalized product recommendations; future AI features expected to deepen insights and improve unit economics.
    • Operational efficiency focus to protect gross margin amid uncertain trade/tariff pressures: localized manufacturing, portfolio optimization, strategic pricing actions.
    • Selling expense plan: core selling expense expected to remain ~40% in Q2 while continuing compensation plan enhancements tied to sales leader productivity and growth.
    • Cost discipline: disciplined controls on G&A while investing in technology and emerging markets (incl. India).

    AI IconMarket Outlook

    • Annual guidance maintained; plan to provide more clarity following Q2.
    • Q2 2026 guidance: revenue $330M-$360M (neutral FX), sequential improvement from Q1; EPS $0.15-$0.25 (sequential improvement).
    • India ramp commentary: not forecasting a lot of revenue in guide; described as learning in 2026 during late-stage pre-market entry, with ramp expected year-by-year thereafter.
    • India planned formal launch: by end of this year (per prepared remarks).

    AI IconRisks & Headwinds

    • Macro pressure on consumers and supply chains; management cited uncertain tariff/trade practices pressures over the past many years.
    • Fuel/energy and geopolitics: monitoring prolonged oil price and broader macro conditions; Ryan referenced fuel costs impacting consumer wallets and margin pressure over time.
    • Near-term switching costs for Prysm iO: behavior change and leader capability shifts from social sellers to Beauty and Wellness consultants.
    • Margin pressure from investment: adjusted operating margin down -280 bps YoY in Q1 due to higher selling and G&A as spending ramps.

    Q&A: Analyst Interest

    • Topic: Prysm iO leader training—what drives successful adoption and conversion. Management detailed a three-part training approach (product/device knowledge, consumer journey/scanning to subscription conversion, and CRM/persistency), plus a “train-the-trainer” certification process in Asia (e.g., Japan, Korea, China) and expansion of certifications into other markets using best practices.
    • Topic: India growth aggressiveness and incentive/infrastructure readiness. Management framed India as a mid-to-long-term priority with cautious sequencing: a ~12-month premarket entry period to learn Indian consumer/entrepreneur behavior, and to dial manufacturing, quality, logistics, distribution, and product formulas before formal launch by year-end; 2026 revenue kept low to emphasize learning.
    • Topic: Capital allocation priorities amid macro and liquidity. Management said capital priorities remain unchanged: fund the business, invest in strategic opportunities, and maintain liquidity; refinance extended liquidity through 2031, while they continue dividends and share repurchases as appropriate, and will pay down debt using the new facility.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the NUS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    📋 Official Regulatory 10-K / 10-Q SEC Filings

    Direct authenticated documentation links to audited SEC database reports for NUS.

    SEC EDGAR Live Feed
    Loading financial data and tables...
    📁

    SEC Filings (NUS)

    © 2026 Stock Market Info — Nu Skin Enterprises, Inc. (NUS) Financial Profile